Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Nerandomilast

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    JASCAYD Gains First Approval for Pulmonary Fibrosis in China
    JASCAYD Gains First Approval for Pulmonary Fibrosis in China

    10 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/10/3202994/0/en/JASCAYD-nerandomilast-receives-first-regulatory-approval-for-progressive-pulmonary-fibrosis-in-China.html

    GLOBENEWSWIRE
    10 Dec 2025
    Share Share
    Jascayd Approved in China for The Treatment of IPF
    Jascayd Approved in China for The Treatment of IPF

    22 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/22/3170892/0/en/JASCAYD-nerandomilast-approved-in-China-for-the-treatment-of-idiopathic-pulmonary-fibrosis-IPF.html

    GLOBENEWSWIRE
    22 Oct 2025
    Share Share
    Boehringer Ingelheim Picks Orsini as Jascayd Specialty Pharmacy
    Boehringer Ingelheim Picks Orsini as Jascayd Specialty Pharmacy

    14 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/orsini-selected-as-specialty-pharmacy-partner-for-boehringer-ingelheims-jascayd-nerandomilast-302582054.html

    PR NEWSWIRE
    14 Oct 2025
    Share Share
    Boehringer Breaks IPF Treatment Drought with New FDA approval
    Boehringer Breaks IPF Treatment Drought with New FDA approval

    09 Oct 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/boehringer-ingelheim-breathes-new-life-lung-fibrosis-treatment-market-fda-approved-jascayd

    FIERCE PHARMA
    09 Oct 2025
    Share Share
    Boehringer Ingelheim’s Jascayd Receives Approval In US
    Boehringer Ingelheim’s Jascayd Receives Approval In US

    07 Oct 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218764

    FDA
    07 Oct 2025
    Share Share
    ERS Data: Nerandomilast Lowers Death Risk in IPF, PPF
    ERS Data: Nerandomilast Lowers Death Risk in IPF, PPF

    30 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-30/pooled-data-presented-at-ers-nerandomilast-monotherapy-linked-to-nominally-significant-reduction-in-risk-of-death-in-ipf-and-ppf

    PHARMAWEB
    30 Sep 2025
    Share Share